Session

Prostate MRI: When do we really need it?

Poster Session 40

  • Location:
    Room Madrid (Hall B2, level 0)
  • Chairs:
     C.L. Dickinson, London (GB)
     M. Emberton, London (GB)
     B.A. Hadaschik, Heidelberg (DE)
  • Aims and objectives of this session

    Prostate MRI is gaining more importance in diagnosis of prostate cancer but the exact indication is still unclear. This session will highlight new data on the indication for an MRI before the first and second biopsy and in active surveillance patients.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 497
Blinded comparison of MRI targeted TRUS guided prostate biopsy and TRUS guided biopsy in the 5th screening round of the European Randomized study of Screening for Prostate Cancer Rotterdam

By: Alberts A.1, Roobol M.1, Bokhorst L.1, Drost F-J.2, Van Leenders G.3, Dwarkasing R.2, Barentsz J.4, Schröder F.1, Bangma C.1, Schoots I.2

Institutes: 1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, 3Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, 4Radboudumc, Dept. of Radiology, Nijmegen, The Netherlands

* 498
The UCL PICTURE trial: A prospective cohort validating study evaluating the accuracy of multi-parametric MRI and prostate HistoScanning compared to transperineal template mapping biopsies in patients requiring risk stratification after prior transrectal prostate biopsy

By: Simmons L.1, Kanthabalan A.1, Hu Y.2, Barrat D.2, Punwani S.3, Ramachandran N.3, Jameson C.4, Freeman A.4, McCartan N.1, Briggs T.5, Gelister J.5, Charman S.6, Van Der Muelen J.6, Moore C.1, Ahmed H.1, Emberton M.1

Institutes: 1University College Hospitals London, Dept. of Surgery and Interventional Science, London, United Kingdom, 2University College London, Centre For Medical Imaging and Computing, London, United Kingdom, 3University College Hospitals London, Dept. of Radiology, London, United Kingdom, 4University College Hospital London, Dept. of Pathology, London, United Kingdom, 5Barnet Hospital, The Royal Free London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 6London School of Hygiene and Tropical Medicine, Dept. of Health Services Research and Policy, London, United Kingdom

* 499
A prospective randomized study comparing standard prostate biopsy and a new diagnostic path with MRI and fusion biopsy: Preliminary results

By: Porpiglia F.1, Mele F.1, Manfredi M.1, Aimar R.1, Checcucci E.1, Cossu M.1, Bollito E.2, Russo F.3, Gned D.4, De Pascale A.4, Cirillo S.5, Fiori C.1

Institutes: 1San Luigi Gonzaga Hospital, Dept. of Urology, University of Turin, Orbassano, Turin, Italy, 2San Luigi Gonzaga Hospital, Dept. of Pathology, University of Turin, Orbassano, Turin, Italy, 3Candiolo Cancer Institute, Division of Radiology, Candiolo, Turin, Italy, 4San Luigi Gonzaga Hospital, Division of Radiology, University of Turin, Orbassano, Turin, Italy, 5Mauriziano Hospital, Division of Radiology, Turin, Italy

500
Multiparametric magnetic resonance imaging and MRI/TRUS-fusion-biopsy for index tumor detection: Correlation with radical prostatectomy specimen

By: Radtke J.P.1, Schwab C.1, Wolf M.2, Freitag M.2, Alt C.3, Kesch C.1, Popeneciu I.V.1, Huettenbrink C.1, Gasch C.1, Klein T.1, Duensing S.4, Roth W.5, Schueler S.6, Stock C.6, Schlemmer H-P.2, Roethke M.C.2, Hohenfellner M.1, Hadaschik B.1

Institutes: 1University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 2German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany, 3Heinrich-Heine University Düsseldorf, Dept. of Radiology, Düsseldorf, Germany, 4University Hospital Heidelberg, Dept. of Urology, Section of Molecular Urooncology, Heidelberg, Germany, 5University of Heidelberg, Dept. of Pathology, Heidelberg, Germany, 6University of Heidelberg, Dept. of Medical Biometry and Informatics, Heidelberg, Germany

501
Is a negative mpMRI really able to rule out significant prostate cancer?

By: Branger N.1, Maubon T.1, Traumann M.1, Thomassin J.2, Pacienca M.2, Brunelle S.3, Salem N.4, Gravis G.5, Walz J.1

Institutes: 1Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, 2Institut Paoli-Calmettes, Dept. of Pathology, Marseille, France, 3Institut Paoli-Calmettes, Dept. of Radiology, Marseille, France, 4Institut Paoli-Calmettes, Dept. of Radiotherapy, Marseille, France, 5Institut Paoli-Calmettes, Dept. of Oncology, Marseille, France

502
Multiparametric MRI and MRI-TRUS fusion-biopsy in patients with prior negative prostate biopsy

By: Kesch C.1, Radtke J.P.1, Roth W.2, Roethke M.3, Schlemmer H.P.3, Hohenfellner M.1, Hadaschik B.1

Institutes: 1University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 2University Hospital Heidelberg, Dept. of Pathology, Heidelberg, Germany, 3German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany

503
Evaluation of PI-RADS classification in prediction of tumor-aggressiveness in targeted biopsy

By: Borkowetz A.1, Platzek I.2, Toma M.3, Renner T.1, Fröhner M.1, Koch R.4, Zastrow S.1, Wirth M.1

Institutes: 1University Hospital, TU Dresden, Dept. of Urology, Dresden, Germany, 2University Hospital, TU Dresden, Dept. of Radiology, Dresden, Germany, 3University Hospital, TU Dresden, Dept. of Pathology, Dresden, Germany, 4University Hospital, TU Dresden, Institute For Medical Informatics and Biometry, Dresden, Germany

504
Poor reproducibility of PI-RADS score in 2 multiparametric MRIs before biopsy in men with elevated PSA

By: Müller S., Løfsgaard L., Estop-Garanto M., Sand T.E., Helgø D., Sund P., Mygland V.

Institutes: Akershus University Hospital, Dept. of Urology, Lørenskog, Norway

505
Targeted PET/TRUS software fusion‑guided biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy: A feasibility study and preliminary results

By: Lopci E.2, Lazzeri M.1, Lughezzani G.1, Pasini L.1, Hurle R.1, Leonardi L.2, Casale P.1, Buffi N.1, Peschechera R.1, Rodari M.2, Zandegiacomo S.1, Benetti A.1, Fiorini G.1, Chiti A.3, Guazzoni G.4

Institutes: 1Istituto Clinico Humanitas IRCCS, Dept. of Urology, Milan, Italy, 2Istituto Clinico Humanitas IRCCS, Dept. of Nuclear Medicine, Milan, Italy, 3Istituto Clinico Humanitas IRCCS-Humanitas University, Dept. of Nuclear Medicine, Milan, Italy, 4Istituto Clinico Humanitas IRCCS-Humanitas University, Dept. of Urology, Milan, Italy

506
MRI guided prostate biopsy: What is the place of PCA3 score?

By: Roumiguie M.1, Beauval J.B.1, Nogueira L.2, Portalez D.3, Soulie M.1, Rischmann P.1, Malavaud B.1

Institutes: 1CHU Rangueil, Dept. of Urology, Toulouse, France, 2CHU Purpan, Dept. of Biology, Toulouse, France, 3CHU Rangueil, Dept. of Radiology, Toulouse, France

507
Low apparent diffusion coefficient (ADC) value is associated with biochemical recurrence in high risk prostate cancer patients

By: Park J., Yoon M.Y., Kim J.K., Kim H.S., Jeong C.W., Ku J.H., Kim H.H., Kwak C.

Institutes: Seoul National University Hospital, Dept. of Urology, Seoul, South Korea

Summary and context
 B.A. Hadaschik, Heidelberg (DE)